Enveric Biosciences, Inc.: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 16, 2020 and accepted by EDGAR at Nov 16, 2020, 06:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $8.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $26.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $6.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $20.8m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-07-01 to 2020-09-30 | $1.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2020-01-01 to 2020-09-30 | $5.6m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2020-07-01 to 2020-09-30 | $2.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2020-01-01 to 2020-09-30 | $7.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$3.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-07-01 to 2020-09-30 | −$27.9k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $11.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$961.2k | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | −$4.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | −$0.20 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | −$1.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | −$0.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | −$1.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 5,289,099 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 4,172,526 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | −$3.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2020-09-30 | $2.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $11.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $28.0m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $14.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $14.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-09-30 | $13.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-20-021409. Last ingested by Listed: Oct 24, 2026, 14:59 ET. Listed shows no prices and gives no investment advice.